Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5277682
Max Phase: Preclinical
Molecular Formula: C44H45F6N7O7S2
Molecular Weight: 698.92
Associated Items:
ID: ALA5277682
Max Phase: Preclinical
Molecular Formula: C44H45F6N7O7S2
Molecular Weight: 698.92
Associated Items:
Canonical SMILES: C[n+]1nn(-c2ccc(-c3nc(CCc4ccc(-c5ccccc5)cc4)c(-c4ccccc4)s3)c(OCCN3CCNC3=O)c2)cc1CCCCN.O=C(O)C(F)(F)F.O=S(=O)([O-])C(F)(F)F
Standard InChI: InChI=1S/C41H43N7O2S.C2HF3O2.CHF3O3S/c1-46-35(14-8-9-23-42)29-48(45-46)34-20-21-36(38(28-34)50-27-26-47-25-24-43-41(47)49)40-44-37(39(51-40)33-12-6-3-7-13-33)22-17-30-15-18-32(19-16-30)31-10-4-2-5-11-31;3-2(4,5)1(6)7;2-1(3,4)8(5,6)7/h2-7,10-13,15-16,18-21,28-29H,8-9,14,17,22-27,42H2,1H3;(H,6,7);(H,5,6,7)
Standard InChI Key: DVTKJUFCVZBHFQ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 698.92 | Molecular Weight (Monoisotopic): 698.3272 | AlogP: 6.62 | #Rotatable Bonds: 15 |
Polar Surface Area: 102.18 | Molecular Species: BASE | HBA: 7 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 9 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 13.55 | CX Basic pKa: 10.20 | CX LogP: 4.08 | CX LogD: 1.47 |
Aromatic Rings: 6 | Heavy Atoms: 51 | QED Weighted: 0.09 | Np Likeness Score: -0.71 |
1. de Lucio H, Revuelto A, Carriles AA, de Castro S, García-González S, García-Soriano JC, Alcón-Calderón M, Sánchez-Murcia PA, Hermoso JA, Gago F, Camarasa MJ, Jiménez-Ruiz A, Velázquez S.. (2022) Identification of 1,2,3-triazolium salt-based inhibitors of Leishmania infantum trypanothione disulfide reductase with enhanced antileishmanial potency in cellulo and increased selectivity., 244 [PMID:36332553] [10.1016/j.ejmech.2022.114878] |
Source(1):